Diversify Wealth Management LLC Has $4.64 Million Position in Zoetis Inc. (NYSE:ZTS)

Diversify Wealth Management LLC grew its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 18.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,821 shares of the company's stock after buying an additional 4,597 shares during the quarter. Diversify Wealth Management LLC's holdings in Zoetis were worth $4,635,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Norges Bank acquired a new position in shares of Zoetis in the fourth quarter valued at approximately $824,321,000. Wellington Management Group LLP increased its position in Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock worth $1,133,755,000 after acquiring an additional 3,059,255 shares during the period. Sarasin & Partners LLP bought a new position in Zoetis during the first quarter worth about $339,111,000. GAMMA Investing LLC increased its position in Zoetis by 14,731.3% during the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock worth $289,666,000 after acquiring an additional 1,747,423 shares during the period. Finally, Polen Capital Management LLC increased its position in Zoetis by 17.5% during the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock worth $1,219,237,000 after acquiring an additional 1,116,541 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 0.3%

NYSE:ZTS opened at $158.81 on Friday. The firm's 50 day simple moving average is $161.37 and its 200 day simple moving average is $161.93. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a market cap of $70.70 billion, a PE ratio of 28.51, a P/E/G ratio of 2.62 and a beta of 0.91.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.38 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.26%. Zoetis's dividend payout ratio is currently 35.91%.

Analyst Ratings Changes

A number of equities analysts recently commented on ZTS shares. Piper Sandler raised their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. UBS Group reduced their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and cut their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $212.13.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.18% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.